Last reviewed · How we verify

LI XIN-XIANG — Portfolio Competitive Intelligence Brief

LI XIN-XIANG pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
mFOLFOX6 or CAPOX mFOLFOX6 or CAPOX phase 3 Platinum-based chemotherapy DNA replication machinery Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Associazione Volontari Pazienti Oncologici · 1 shared drug class
  2. AstraZeneca · 1 shared drug class
  3. Barts & The London NHS Trust · 1 shared drug class
  4. CatalYm GmbH · 1 shared drug class
  5. Centre Leon Berard · 1 shared drug class
  6. Centre Oscar Lambret · 1 shared drug class
  7. Chinese Academy of Medical Sciences · 1 shared drug class
  8. Air Force Military Medical University, China · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for LI XIN-XIANG:

Cite this brief

Drug Landscape (2026). LI XIN-XIANG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/li-xin-xiang. Accessed 2026-05-16.

Related